|
|
|
| Response to pretransplant downstaging therapy predicts patient outcome after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus |
| Zhe Yang a , Jing-Qi Sun b , Shuo Wang a , Li Zhuang a , Shu-Sen Zheng a , b , ∗ |
a Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou 310022, China
b Division of Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
∗ Corresponding author at: Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, 848 Dongxin Road, Hangzhou 310022, China.
E-mail address: shusenzheng@zju.edu.cn (S.-S. Zheng). |
|
|
|
|
Abstract Downstaging therapy has been confirmed to help patients whose tumors are beyond the liver transplantation (LT) criteria to gain the opportunity for LT with long-term survival. Zhan et al. [1] recently demonstrated that patients with hepatocellular carcinoma (HCC) beyond the Hangzhou criteria on initial diagnosis without extrahepatic metastasis or vascular invasion have comparative outcomes with those matching Milan criteria after LT if these patients are successfully downstaged to the Hangzhou criteria [1]. However, whether the downstaging therapy prolongs the survival time of those with portal vein tumor thrombosis (PVTT) is not clear. Our study was to add some data in this field.
|
|
|
|
|
|
|
|
|
2022, Vol. 21 
